UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

New‐onset posttransplant diabetes mellitus after haploidentical hematopoietic cell transplantation with posttransplant cyclophosphamide

EJHaem, 2020-11, Vol.1 (2), p.576-580

2020

Volltextzugriff (PDF)

Maintenance Strategies After Hematopoietic Cell Transplantation

Pharmacotherapy, 2020-08, Vol.40 (8), p.727-740

2020

Volltextzugriff (PDF)

Novel targets in the treatment of advanced melanoma: new first-line treatment options

The Annals of pharmacotherapy, 2013-04, Vol.47 (4), p.519-526

2013

Volltextzugriff (PDF)

Risk factors associated with early viral reactivation following haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide: a pilot study

Annals of hematology, 2020-05, Vol.99 (5), p.1137-1139

2020

Volltextzugriff (PDF)

Haploidentical Bone Marrow Transplantation with Post-Transplantation Cyclophosphamide Plus Thiotepa Improves Donor Engraftment in Patients with Sickle Cell Anemia: Results of an International Learning Collaborative

Biology of blood and marrow transplantation, 2019-06, Vol.25 (6), p.1197-1209

2019

Volltextzugriff (PDF)

Outcomes of a novel rituximab-based non-myeloablative conditioning regimen for hematopoietic cell transplantation in severe aplastic anemia

Bone marrow transplantation (Basingstoke), 2018-06, Vol.53 (6), p.795-799

2018

Volltextzugriff (PDF)

Defining Incidence and Risk Factors for Catheter-Associated Bloodstream Infections in an Outpatient Adult Hematopoietic Cell Transplantation Program

Biology of blood and marrow transplantation, 2018-10, Vol.24 (10), p.2081-2087

2018

Volltextzugriff (PDF)

American Society for Blood and Marrow Transplantation Pharmacy Special Interest Group Survey on Chimeric Antigen Receptor T Cell Therapy Administrative, Logistic, and Toxicity Management Practices in the United States

Biology of blood and marrow transplantation, 2019-01, Vol.25 (1), p.26-33

2019

Volltextzugriff (PDF)

Alternative agents to vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections

American journal of therapeutics, 2013-03, Vol.20 (2), p.200-212

2013

Volltextzugriff (PDF)

Reduction in Prevalence of Thrombotic Events in Sickle Cell Disease after Allogeneic Hematopoietic Stem Cell Transplantation

Blood, 2020-11, Vol.136 (Supplement 1), p.12-12

2020

Volltextzugriff (PDF)

Reduced Insulin Sensitivity in Patients with Myeloid Malignancies and Clonal Hematopoiesis Mutations

Blood, 2020-11, Vol.136 (Supplement 1), p.27-28

2020

Volltextzugriff (PDF)

Preparative Regimen Dosing for Hematopoietic Stem Cell Transplantation in Patients with Chronic Hepatic Impairment: Analysis of the Literature and Recommendations

Biology of blood and marrow transplantation, 2014-05, Vol.20 (5), p.622-629

2014

Volltextzugriff (PDF)

Increased Incidence of New-Onset Diabetes Mellitus Type II Following Haploidentical Bone Marrow Transplant with Post-Transplant Cyclophosphamide for Sickle Cell Disease

Blood, 2020-11, Vol.136 (Supplement 1), p.20-20

2020

Volltextzugriff (PDF)

Venetoclax-Based Salvage Therapy for Post-Hematopoietic Cell Transplantation Relapse in Acute Myeloid Leukemia

Blood, 2019-11, Vol.134 (Supplement_1), p.2643-2643

2019

Volltextzugriff (PDF)

Outcomes of Non-Myeloablative HLA-Haploidentical Bone Marrow Transplant with Thiotepa and Post-Transplant Cyclophosphamide in Children and Adults with Severe Sickle Cell Disease, a Phase II Trial: Vanderbilt Global Haploidentical Transplant Learning Collaborative (VGC2)

Blood, 2020-11, Vol.136 (Supplement 1), p.8-9

2020

Volltextzugriff (PDF)

Outcomes of a Novel Rituximab-Based Non-Ablative Conditioning Regimen for Hematopoietic Cell Transplantation in Severe Aplastic Anemia

Blood, 2017-12, Vol.130, p.3210-3210

2017

Volltextzugriff (PDF)

Immunosuppressive agents and monitoring in long‐term survivors

Blood and Marrow Transplantation Long Term Management, 2021, p.381-392

2021

Volltextzugriff (PDF)

Incidence and Outcomes of Early Fever Following Haploidentical Hematopoietic Cell Transplant with Post-Transplant Cyclophosphamide

Transplantation and cellular therapy, 2021-03, Vol.27 (3), p.S465-S466

2021

Volltextzugriff (PDF)

Evaluating the Clinical Benefit of Post-Transplant DNA Methyltransferase Inhibitor (DNMTi) Maintenance in MDS/AML

Transplantation and cellular therapy, 2021-03, Vol.27 (3), p.S143-S144

2021

Volltextzugriff (PDF)

New-onset post-transplant diabetes mellitus after haploidentical hematopoietic cell transplant with post-transplant cyclophosphamide

EJHaem, 2020-11, Vol.1 (2), p.576-580

2020

Volltextzugriff (PDF)

Risk Factors for Viral Infections Following Haploidentical Hematopoietic Stem Cell Transplantation (Haplo-HCT) with Post-Transplant Cyclophosphamide (PTCy) in Patients with Various Hematologic Disorders: A Single Center Experience

Biology of blood and marrow transplantation, 2018-03, Vol.24 (3), p.S334

2018

Volltextzugriff (PDF)

77 - Minimal Residual Disease (MRD) Negativity and Lenalidomide Maintainence Therapy are Associated with Superior Survival Outcomes in Multiple Myeloma

Biology of blood and marrow transplantation, 2018-03, Vol.24 (3), p.S76-S77

2018

Volltextzugriff (PDF)

402 - Risk Factors for Viral Infections Following Haploidentical Hematopoietic Stem Cell Transplantation (Haplo-HCT) with Post-Transplant Cyclophosphamide (PTCy) in Patients with Various Hematologic Disorders: A Single Center Experience

Biology of blood and marrow transplantation, 2018-03, Vol.24 (3), p.S334-S334

2018

Volltextzugriff (PDF)

Minimal Residual Disease (MRD) Negativity and Lenalidomide Maintainence Therapy are Associated with Superior Survival Outcomes in Multiple Myeloma

Biology of blood and marrow transplantation, 2018-03, Vol.24 (3), p.S76-S77

2018

Volltextzugriff (PDF)

Reduced Central Line–Associated Bloodstream Infections (CLABSI) and Its Sequelae Amongst Recipients of Allogeneic Hematopoietic Stem Cell Transplant in the Outpatient Setting

Biology of blood and marrow transplantation, 2018-03, Vol.24 (3), p.S337

2018

Volltextzugriff (PDF)

1 – 25 von 60

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(35)
Mit Volltextzugriff
(53)

Publikationsform

Artikel
(58)
Buchkapitel
(2)

Sprache

Englisch
(60)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(23)
Science & Technology
(23)
Exercise
(16)
Humans
(15)
Quality Of Life
(11)
Physical Fitness
(9)
Hematology
(8)
Oncology
(8)
Transplantation
(8)
Cancer
(7)
Female
(6)
Adult
(5)
Immunology
(5)
Middle Aged
(5)
Cancer Therapies
(4)
Caregivers
(4)
Hematology, Oncology And Palliative Medicine
(4)
Mental Health
(4)
Nursing
(4)
Pharmacology & Pharmacy
(4)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

New‐onset posttransplant diabetes mellitus after haploidentical hematopoietic cell transplantation with posttransplant cyclophosphamide

Maintenance Strategies After Hematopoietic Cell Transplantation

Novel targets in the treatment of advanced melanoma: new first-line treatment options

Risk factors associated with early viral reactivation following haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide: a pilot study

Haploidentical Bone Marrow Transplantation with Post-Transplantation Cyclophosphamide Plus Thiotepa Improves Donor Engraftment in Patients with Sickle Cell Anemia: Results of an International Learning Collaborative

Outcomes of a novel rituximab-based non-myeloablative conditioning regimen for hematopoietic cell transplantation in severe aplastic anemia

Defining Incidence and Risk Factors for Catheter-Associated Bloodstream Infections in an Outpatient Adult Hematopoietic Cell Transplantation Program

American Society for Blood and Marrow Transplantation Pharmacy Special Interest Group Survey on Chimeric Antigen Receptor T Cell Therapy Administrative, Logistic, and Toxicity Management Practices in the United States

Alternative agents to vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections

Reduction in Prevalence of Thrombotic Events in Sickle Cell Disease after Allogeneic Hematopoietic Stem Cell Transplantation

Reduced Insulin Sensitivity in Patients with Myeloid Malignancies and Clonal Hematopoiesis Mutations

Preparative Regimen Dosing for Hematopoietic Stem Cell Transplantation in Patients with Chronic Hepatic Impairment: Analysis of the Literature and Recommendations

Increased Incidence of New-Onset Diabetes Mellitus Type II Following Haploidentical Bone Marrow Transplant with Post-Transplant Cyclophosphamide for Sickle Cell Disease

Venetoclax-Based Salvage Therapy for Post-Hematopoietic Cell Transplantation Relapse in Acute Myeloid Leukemia

Outcomes of Non-Myeloablative HLA-Haploidentical Bone Marrow Transplant with Thiotepa and Post-Transplant Cyclophosphamide in Children and Adults with Severe Sickle Cell Disease, a Phase II Trial: Vanderbilt Global Haploidentical Transplant Learning Collaborative (VGC2)

Outcomes of a Novel Rituximab-Based Non-Ablative Conditioning Regimen for Hematopoietic Cell Transplantation in Severe Aplastic Anemia

Immunosuppressive agents and monitoring in long‐term survivors

Incidence and Outcomes of Early Fever Following Haploidentical Hematopoietic Cell Transplant with Post-Transplant Cyclophosphamide

Evaluating the Clinical Benefit of Post-Transplant DNA Methyltransferase Inhibitor (DNMTi) Maintenance in MDS/AML

New-onset post-transplant diabetes mellitus after haploidentical hematopoietic cell transplant with post-transplant cyclophosphamide

Risk Factors for Viral Infections Following Haploidentical Hematopoietic Stem Cell Transplantation (Haplo-HCT) with Post-Transplant Cyclophosphamide (PTCy) in Patients with Various Hematologic Disorders: A Single Center Experience

77 - Minimal Residual Disease (MRD) Negativity and Lenalidomide Maintainence Therapy are Associated with Superior Survival Outcomes in Multiple Myeloma

402 - Risk Factors for Viral Infections Following Haploidentical Hematopoietic Stem Cell Transplantation (Haplo-HCT) with Post-Transplant Cyclophosphamide (PTCy) in Patients with Various Hematologic Disorders: A Single Center Experience

Minimal Residual Disease (MRD) Negativity and Lenalidomide Maintainence Therapy are Associated with Superior Survival Outcomes in Multiple Myeloma

Reduced Central Line–Associated Bloodstream Infections (CLABSI) and Its Sequelae Amongst Recipients of Allogeneic Hematopoietic Stem Cell Transplant in the Outpatient Setting

Suchergebnisse filtern